Gianpaolo Pirovano1, Mieczyslaw Pasowicz2,
Miles A. Kirchin3, Ningyan Shen4, John R. Parker5,
Alberto Spinazzi1
1Medical Affairs, Bracco Diagnostics
Inc., Princeton, NJ, United States; 2Radiology, John Paul II
Hospital, Kracow, Poland; 3Medical Communications, Bracco Imaging,
Milan, Italy; 4Biometrics, Bracco Diagnostics Inc., Princeton, NJ,
United States; 5Medical Communications, Bracco Diagnostics Inc.,
Princeton, NJ, United States
15
subjects aged 2-5 years were enrolled in a pharmacokinetic study and received
0.1 mmol/kg bw gadobenate dimeglumine.
Pharmacokinetic parameters were calculated from the blood Gd
concentration-time data using compartmental and noncompartmental techniques.
At 6 hours after gadobenate dimeglumine administration, all subjects residual
Gd in blood was close to 1.0 g/mL, indicating that Gd was successfully
cleared from the blood. No differences in whole blood or urinary
pharmacokinetic parameters were observed between pediatric subjects 2 to 5
years when compared to adult subjects studied in previously.
Keywords